The content on this website is intended solely for veterinarians and other animal health professionals.
By using this website, you confirm that the above applies to you.
Positive results from Strangvac clinical trials published in scientific journal Vaccine
Results and analyses from clinical trials on the Strangvac® vaccine research project have been published online in the leading scientific journal ‘Vaccine’. The article highlights that Strangvac® is safe and provides significant levels of protection to horses against...Intervacc awarded funding from Vinnova for further development of vaccine against Staphylococcus aureus infections
Stockholm 25 March 2020 – Intervacc AB (publ) will continue the development of its new vaccine against Staphylococcus aureus infections that cause mastitis in dairy cows. The project will be co-financed by Intervacc and Vinnova within the framework of innovation...The European Medicines Agency confirms that Intervacc’s application for the granting of a Community marketing authorization for Strangvac is complete and correctly submitted
Stockholm March 18, 2020 – Intervacc AB (publ) announces that the European Medicines Agency, EMA, has today confirmed that the company’s application for the granting of a Community marketing authorization for Strangvac is complete and correctly submitted....Intervacc announces submission of the Marketing Authorization Application for Strangvac to the European Medicines Agency
Stockholm February 26, 2020 – Intervacc AB (publ) announces that the Company’s Marketing Authorization Application (MAA) for review of Strangvac® has been submitted today to the European Medicines Agency (EMA). Intervacc is seeking approval for Strangvac® as a...Nyhetstjänster
